Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia
TFPI Inhibitors Have 20 Years Of Bad History
Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.
